CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We have now added a new section called the "Assay History List" to the "At A Gla...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...